REL, REL proto-oncogene, NF-kB subunit, 5966

N. diseases: 90; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1709781
Disease: Pyothorax-Associated Lymphoma
Pyothorax-Associated Lymphoma 		0.010 Biomarker disease BEFREE Here we examined T-lymphocyte subsets as well as c-myc and REL gene amplification in PAL tissues. 11493333 2001
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.550 Biomarker disease BEFREE BCL11A coamplified with REL in B-NHL cases and HD lymphoma cell lines with gains and amplifications of 2p13, suggesting that BCL11A may be involved in lymphoid malignancies through either chromosomal translocation or amplification. 11719382 2001
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.020 GeneticVariation disease BEFREE However, by molecular cloning of t(2;14)(p13;q32.3) from 3 cases of aggressive B-cell chronic lymphocytic leukemia (CLL)/immunocytoma, this study has shown clustered breakpoints on chromosome 2p13 immediately upstream of a CpG island located about 300 kb telomeric of REL. 11719382 2001
CUI: C1333064
Disease: Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma 		0.050 Biomarker disease BEFREE The imbalance pattern of cHL subtypes suggests that different molecular pathways are activated, with REL or other genes on chromosomal band 2p15-p16 playing a fundamental role in the pathogenesis of classical Hodgkin lymphoma. 11830490 2002
CUI: C2347747
Disease: Adult Classical Hodgkin Lymphoma
Adult Classical Hodgkin Lymphoma 		0.040 Biomarker disease BEFREE The imbalance pattern of cHL subtypes suggests that different molecular pathways are activated, with REL or other genes on chromosomal band 2p15-p16 playing a fundamental role in the pathogenesis of classical Hodgkin lymphoma. 11830490 2002
CUI: C0152268
Disease: Nodular Sclerosis Classical Hodgkin Lymphoma
Nodular Sclerosis Classical Hodgkin Lymphoma 		0.010 Biomarker disease BEFREE The high frequency of 2p overrepresentations including REL, particularly in cHL-NS (88%), suggests that an alternative mechanism of constitutive activation of nuclear factor NF-kappaB is a hallmark of HRS cells. 11830490 2002
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.550 GeneticVariation disease LHGDN Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. 11830502 2002
CUI: C1333064
Disease: Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma 		0.050 Biomarker disease BEFREE These data indicate that REL rather than BCL11A may be the target of the 2p13 alterations in cHL. 11830502 2002
CUI: C2347747
Disease: Adult Classical Hodgkin Lymphoma
Adult Classical Hodgkin Lymphoma 		0.040 Biomarker disease BEFREE These data indicate that REL rather than BCL11A may be the target of the 2p13 alterations in cHL. 11830502 2002
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 AlteredExpression group BEFREE Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. 11921291 2002
CUI: C0035335
Disease: Retinoblastoma
Retinoblastoma 		0.010 GeneticVariation disease BEFREE Twenty-five primary retinoblastoma tumours were analysed by real-time quantitative polymerase chain reaction to determine the genomic copy number of the N-MYC gene (2p24) relative to the copy number for REL, B2M, ALB, AF10 and MLL. 12232763 2002
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.550 Biomarker disease BEFREE Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. 12478664 2003
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.550 AlteredExpression disease LHGDN Our data confirm previous cytogenetic results from primary Hodgkin's tumors suggesting an important pathogenic role of REL and JAK2 in this disease. 12478664 2003
CUI: C0220597
Disease: Adult Hodgkin Lymphoma
Adult Hodgkin Lymphoma 		0.310 Biomarker disease BEFREE Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. 12478664 2003
CUI: C0220644
Disease: Childhood Hodgkin Lymphoma
Childhood Hodgkin Lymphoma 		0.010 Biomarker disease BEFREE Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. 12478664 2003
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that directs the production of a chimeric protein, termed REL-NRG (Non-Rel Gene). 12483529 2002
CUI: C1333064
Disease: Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma 		0.050 Biomarker disease BEFREE The data suggest that REL aberrations are a genetic mechanism contributing to constitutive nuclear factor (NF)-kappa B/Rel activation in cHL. 12511414 2003
CUI: C2347747
Disease: Adult Classical Hodgkin Lymphoma
Adult Classical Hodgkin Lymphoma 		0.040 Biomarker disease BEFREE The data suggest that REL aberrations are a genetic mechanism contributing to constitutive nuclear factor (NF)-kappa B/Rel activation in cHL. 12511414 2003
CUI: C0376544
Disease: Hematopoietic Neoplasms
Hematopoietic Neoplasms 		0.010 GeneticVariation group BEFREE Amplification, overexpression, or rearrangement of the c-rel gene, encoding the c-Rel NF-kappaB subunit, has been reported in solid and hematopoietic malignancies. 12897145 2003
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group BEFREE The REL gene is amplified in many human B-cell lymphomas and we have previously shown that expression of REL from a retroviral vector can malignantly transform chicken spleen cells in vitro. 14534540 2003
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.070 Biomarker group BEFREE Taken together, these results suggest the following: (1) that REL must activate transcription to transform cells in vitro; (2) that a reduced level of transactivation enhances the oncogenicity of REL; (3) that REL shuttles from the cytoplasm to the nucleus in transformed chicken spleen cells; and (4) that mutations in REL, in addition to amplifications, could activate its oncogenicity in human lymphomas. 14534540 2003
CUI: C1608408
Disease: Malignant transformation
Malignant transformation 		0.010 Biomarker phenotype BEFREE To identify REL protein functions necessary for malignant transformation, we have performed deletion analysis on REL sequences encoding residues of two C-terminal subdomains that are involved in transcriptional activation. 14534540 2003
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.100 Biomarker group LHGDN Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. 14615382 2004
CUI: C0079744
Disease: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma 		0.070 Biomarker disease BEFREE Nonetheless, these data indicate that DLBCLs are heterogeneous with respect to REL and thus nuclear factor-kappaB (NF-kappaB) activity. 14615382 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 Biomarker group BEFREE We show that overexpression of wild-type mouse and human c-rel genes suffices to malignantly transform primary spleen cells in stringent soft agar assays and produce fatal tumors in vivo. 14647412 2004